NAI联合BCG在BCG无应答乳头状非肌层浸润性膀胱癌中延长无进展生存、无病生存并避免膀胱切除
QUILT-3.032研究评估了IL-15受体激动剂NAI联合BCG治疗BCG无应答的高级别乳头状非肌层浸润性膀胱癌的疗效。36个月随访显示,12、24、36个月无病生存率分别为58.2%、52.1%、38.2%,无进展生存率12和36个月分别为94.9%和83.1%,膀胱切除避免率12和36个月分别为92.2%和81.8%,安全性良好。
要点
- NAI联合BCG在BCG无应答乳头状NMIBC中36个月DFS为38.2%,PFS为83.1%。
- 36个月膀胱切除避免率达81.8%,中位至膀胱切除时间未达到。
- 治疗相关不良事件多为1-2级(61%),3级仅3%,无4-5级。
核心结论
- NAI联合BCG在BCG无应答乳头状NMIBC中显示出持久的无病生存、无进展生存、疾病特异性生存和膀胱切除避免率,且安全性可控。
研究设计与样本
- QUILT-3.032(NCT03022825)是一项开放标签、多中心研究,纳入BCG无应答的高级别Ta/T1乳头状NMIBC患者,接受400 μg NAI联合50 mg BCG膀胱内灌注,每周一次连续6周。
- 主要终点为12个月无病生存率,同时评估无进展生存、疾病特异性生存、膀胱切除避免率及治疗相关不良事件。
主要发现
- 12、24、36个月无病生存率分别为58.2%(95% CI: 46.6, 68.2)、52.1%(95% CI: 40.3, 62.7)、38.2%(95% CI: 25.6, 50.6)。
- 12和36个月无进展生存率分别为94.9%(95% CI: 86.9, 98.0)和83.1%(95% CI: 69.5, 91.0)。
- 12和36个月疾病特异性生存率分别为98.7%(95% CI: 91.4, 99.8)和96.0%(95% CI: 88.2, 98.7),中位疾病特异性生存未达到。
- 12和36个月膀胱切除避免率分别为92.2%(95% CI: 83.4, 96.4)和81.8%(95% CI: 68.1, 90.1),中位至膀胱切除时间未达到。
- 大多数治疗相关不良事件为1-2级(61%),3级为3%,无4-5级事件。
临床怎么用
- 对于BCG无应答的高级别乳头状NMIBC患者,NAI联合BCG可作为保留膀胱的治疗选择,需关注长期随访中的无病生存和进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In QUILT-3.032, the efficacy of interleukin-15 receptor agonist, nogapendekin alfa inbakicept (NAI), in combination with bacillus Calmette-Guérin (BCG) for BCG-unresponsive high-grade papillary-only nonmuscle-invasive bladder cancer was assessed. In this study, we report the 36-month follow-up among participants with BCG-unresponsive papillary disease (cohort B). MATERIALS AND METHODS: NCT03022825 is an open-label, multicenter study of patients with BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer who received 400 μg NAI plus 50 mg BCG intravesically weekly for 6 consecutive weeks. The primary end point is disease-free survival (DFS) at 12 months. Progression-free survival (PFS), disease-specific survival (DSS), and cystectomy avoidance were assessed. Treatment-related adverse events were assessed. RESULTS: At July 15, 2024, data cutoff, the DFS rates at 12, 24, and 36 months were 58.2% (95% CI: 46.6, 68.2), 52.1% (95% CI: 40.3, 62.7), and 38.2% (95% CI: 25.6, 50.6), respectively. The PFS rates at 12 and 36 months were 94.9% (95% CI: 86.9, 98.0) and 83.1% (95% CI: 69.5, 91.0). The DSS rates at 12 and 36 months were 98.7% (95% CI: 91.4, 99.8) and 96.0% (95% CI: 88.2, 98.7). The median DSS has not been reached. Cystectomy avoidance rates at 12 and 36 months were 92.2% (95% CI: 83.4, 96.4) and 81.8% (95% CI: 68.1, 90.1), with median time to cystectomy not reached. Most treatment-related adverse events were grade 1 to 2 (61%) with 3% grade 3 and no grade 4 to 5. CONCLUSIONS: The 12-month and 36-month DFS, PFS, DSS, and cystectomy avoidance rates demonstrate the effectiveness and safety of NAI plus BCG in the management of BCG-unresponsive papillary disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03022825.
引用
- Chang SS, Chamie K, Kramolowsky E, et al. Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. J Urol. 2025. PMID: 40956664. doi:10.1097/JU.0000000000004782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。